Exact Sciences Corporation (EXAS)

Healthcare
$104.91▲ 0.00 (0.00%)
Real-time prices · US Markets
Earnings in 4dMay 7, 2026
Bearish
4.7 / 10
Healthy balance sheet and financial position.
currently unprofitable (-6% margin).
Quality
2.9
Health
6.9
Growth
6.5
Valuation
4.2
Sentiment
3.3
Analyst Target
$106.30
▲ +1.3% from current

Price Chart

Data not available.

Fundamentals

Trailing P/E
price-to-earnings
Forward P/E
55.2×
next 12 months est.
Market Cap
$20.0B
market capitalization
Div Yield
dividend yield
Profit Margin
-6.4%
net profit margin
Gross Margin
69.7%
revenue minus COGS
ROE
-8.7%
return on equity
Beta
1.44
vs S&P 500
Price / Book
P/B ratio
52-Week Range
$39 — $105
annual min — max

EPS — Estimate vs Actual

Frequently Asked Questions

Is EXAS a good stock to buy right now?
Exact Sciences Corporation's Q·Score is 4.7/10 (Bearish), reflecting its current fundamentals, analyst data, and valuation metrics. Healthy balance sheet and financial position. Key area to monitor: currently unprofitable (-6% margin). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for EXAS?
The consensus price target for EXAS is $106.30, based on ratings from 10 Wall Street analysts. This is 1.3% above the current price of $104.91. Price targets are forward-looking estimates and not guarantees of future performance.
Is EXAS overvalued or undervalued?
Exact Sciences Corporation (EXAS) scores below peers on valuation metrics, trading above typical sector multiples. Its forward P/E ratio stands at 55.2×.
When does Exact Sciences Corporation report its next earnings?
Exact Sciences Corporation is scheduled to report earnings in 4 days, on May 7, 2026.
What is Exact Sciences Corporation's profit margin?
Exact Sciences Corporation has a net profit margin of -6.4%, indicating the company is currently operating at a net loss. Its gross margin stands at 69.7%, indicating a high-margin business model.
Is Exact Sciences Corporation's revenue growing?
Exact Sciences Corporation is reporting strong year-over-year growth of 23.1%.
How much debt does Exact Sciences Corporation have?
Exact Sciences Corporation has a debt-to-equity ratio of 1.06×, reflecting a moderately high debt load — watch cash flow coverage. Its current ratio is 2.43×, indicating comfortable short-term liquidity.